• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NQ:AZN)

    91.59 +1.05 (+1.16%)
    Streaming Delayed Price Updated: 11:05 AM EST, Jan 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about AstraZeneca PLC - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    15 16 Next >
    News headline image
    Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
    From AstraZeneca
    Via Business Wire
    News headline image
    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
    From AstraZeneca
    Via Business Wire
    News headline image
    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca's 9M and Q3 2025 Financial Results
    From AstraZeneca
    Via Business Wire
    News headline image
    Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca unveils expanded manufacturing facility in Texas
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
    From AstraZeneca
    Via Business Wire
    News headline image
    Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
    From AstraZeneca
    Via Business Wire
    News headline image
    DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
    From AstraZeneca
    Via Business Wire
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    News headline image
    SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
    From AstraZeneca
    Via Business Wire
    News headline image
    TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
    From AstraZeneca
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    15 16 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.